ES2973524T3 - Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T - Google Patents

Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T Download PDF

Info

Publication number
ES2973524T3
ES2973524T3 ES20176483T ES20176483T ES2973524T3 ES 2973524 T3 ES2973524 T3 ES 2973524T3 ES 20176483 T ES20176483 T ES 20176483T ES 20176483 T ES20176483 T ES 20176483T ES 2973524 T3 ES2973524 T3 ES 2973524T3
Authority
ES
Spain
Prior art keywords
cell
primary
cells
transduction
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20176483T
Other languages
English (en)
Spanish (es)
Inventor
Bitao Liang
Wei Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ES2973524T3 publication Critical patent/ES2973524T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5156Animal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases [EC 2.]
    • C12N2501/727Kinases (EC 2.7.)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells
    • C12N2510/02Cells for production
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15042Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES20176483T 2014-07-11 2015-07-10 Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T Active ES2973524T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462023618P 2014-07-11 2014-07-11

Publications (1)

Publication Number Publication Date
ES2973524T3 true ES2973524T3 (es) 2024-06-20

Family

ID=55064944

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20176483T Active ES2973524T3 (es) 2014-07-11 2015-07-10 Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T
ES15818898T Active ES2813437T3 (es) 2014-07-11 2015-07-10 Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES15818898T Active ES2813437T3 (es) 2014-07-11 2015-07-10 Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T

Country Status (5)

Country Link
US (2) US10982189B2 (2)
EP (2) EP3750993B1 (2)
JP (3) JP6754761B2 (2)
ES (2) ES2973524T3 (2)
WO (1) WO2016007827A1 (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064153A1 (en) 2013-03-15 2015-03-05 The Trustees Of Princeton University High efficiency microfluidic purification of stem cells to improve transplants
EP3608022A1 (en) 2013-03-15 2020-02-12 The Trustees of Princeton University Methods and devices for high throughput purification
EP3569313A1 (en) 2013-03-15 2019-11-20 GPB Scientific, LLC On-chip microfluidic processing of particles
US12590955B2 (en) 2013-03-15 2026-03-31 Zeon Corporation Methods and systems for processing particles
JP6754761B2 (ja) * 2014-07-11 2020-09-16 セルジーン コーポレイション Tリンパ球へのベクター導入効率の改善方法
US10976232B2 (en) 2015-08-24 2021-04-13 Gpb Scientific, Inc. Methods and devices for multi-step cell purification and concentration
EP3675876A4 (en) 2017-09-01 2021-06-02 GPB Scientific, Inc. METHOD FOR PRODUCING THERAPEUTICALLY ACTIVE CELLS USING MICROFLUIDICS
DE102018100967B4 (de) 2018-01-17 2019-08-14 Immatics US, Inc. Verfahren zur feststellung der wirksamkeit von viralen vektoren
DE102018010282A1 (de) 2018-01-17 2019-07-18 Immatics US, Inc. Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
US20220267726A1 (en) 2019-07-18 2022-08-25 Gpb Scientific, Inc. Ordered processing of blood products to produce therapeutically active cells
US20230028754A1 (en) 2019-12-28 2023-01-26 Gpb Scientific, Inc. Microfluidic cartridges for processing particles and cells
EP4320226A4 (en) * 2021-04-06 2025-08-06 Unicet Biotech Llc METHODS FOR IMPROVING THE STABILITY OF VIRAL TRANSDUCTION OF GAMMA DELTA T CELLS AND RELATED APPLICATIONS
WO2023286088A1 (en) * 2021-07-16 2023-01-19 Indian Institute Of Science Education And Research Bhopal Methods and compositions for viral vector transduction
WO2025180499A1 (zh) * 2024-02-28 2025-09-04 南京因领生物科技有限公司 一种提高细胞中病毒包装产量或质量的方法
CN119530302B (zh) * 2025-01-22 2025-06-27 青岛华赛伯曼医学细胞生物有限公司 提高til细胞的慢病毒转导效率及转导稳定性的方法及试剂盒

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
WO1996034970A1 (en) * 1995-05-04 1996-11-07 United States Of America, Represented By The Secretary Of The Navy Improved methods for transfecting t cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US5948893A (en) 1996-01-17 1999-09-07 The United States Of America As Represented By The Secretary Of The Navy Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP1849873B1 (en) 1999-04-29 2011-10-12 Gbp Ip, Llc Method and means for producing high titer, safe, recombinant lentivirus vectors
EP2316918B1 (en) 2001-02-14 2015-07-01 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
US20060210536A1 (en) * 2003-04-17 2006-09-21 Curt Horvath Methods and compositions for inhibiting stat signaling pathways
ATE488252T1 (de) * 2003-05-05 2010-12-15 Virxsys Corp Erhöhte transduktion mit abc- transportersubstratenhemmern
AU2006214278C1 (en) * 2005-02-16 2012-07-19 Miltenyi Biotec Technology, Inc. Lentiviral vectors and their use
GB0526255D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
PL2471907T3 (pl) 2005-12-29 2019-07-31 Celularity, Inc. Populacje komórek macierzystych łożyska
JP5666903B2 (ja) * 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ, インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
RU2536242C2 (ru) 2007-09-28 2014-12-20 Антродженезис Корпорейшн Угнетение опухолей с помощью плацентарного перфузата человека и выделенных из плаценты человека вспомогательных натуральных клеток-киллеров
RU2015130665A (ru) 2008-11-19 2018-12-24 Антродженезис Корпорейшн Амниотические адгезивные клетки
MX342995B (es) 2010-07-13 2016-10-21 Anthrogenesis Corp Métodos de generar células asesinas naturales.
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
DK3763820T3 (da) * 2012-02-29 2022-02-07 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Retroviral transduktion ved hjælp af poloxamerer
EA033110B1 (ru) * 2012-04-11 2019-08-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерный рецептор антигена, направленный на антиген созревания b-клеток, кодирующая его нуклеиновая кислота, соответствующие экспрессионный вектор, клетка-хозяин, применения и способы
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
JP6754761B2 (ja) * 2014-07-11 2020-09-16 セルジーン コーポレイション Tリンパ球へのベクター導入効率の改善方法

Also Published As

Publication number Publication date
EP3167058A4 (en) 2017-12-13
ES2813437T3 (es) 2021-03-23
JP2020191901A (ja) 2020-12-03
JP6754761B2 (ja) 2020-09-16
US20170166866A1 (en) 2017-06-15
US20210309966A1 (en) 2021-10-07
EP3750993B1 (en) 2023-12-27
EP3167058A1 (en) 2017-05-17
US11629335B2 (en) 2023-04-18
JP2017521101A (ja) 2017-08-03
EP3750993A1 (en) 2020-12-16
JP2023040152A (ja) 2023-03-22
EP3167058B1 (en) 2020-05-27
WO2016007827A1 (en) 2016-01-14
US10982189B2 (en) 2021-04-20

Similar Documents

Publication Publication Date Title
ES2973524T3 (es) Métodos para mejorar la eficacia de la transducción de vectores en los linfocitos T
US11806365B2 (en) Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
AU2014214850B2 (en) Modified T lymphocytes having improved specificity
ES2703747T3 (es) Receptores de antígenos quiméricos
JP2023011593A (ja) リンパ節のb細胞領域、皮膚、または消化管にホーミングするように操作されたcar-t細胞
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
HK1234782A1 (en) Methods of improving vector transduction efficiency into t lymphocytes
HK1234782B (en) Methods of improving vector transduction efficiency into t lymphocytes
AU2017204617B2 (en) Chimeric antigen receptors
HK40022493A (en) Modified t lymphocytes having improved specificity